All In Biotech

Drug Trial Radar · NCT06179108

Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia

A Randomized, Double-blinded, Placebo-controlled, Multicenter Study to Evaluate the Antipsychotic Efficacy and Safety of LB-102 in the Treatment of Adult Patients With Acute Schizophrenia

Last checked: Nov 19, 2026Latest source record: Oct 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 359 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

359

Actual

Start

Nov 29, 2023

Primary completion

Dec 4, 2024

Study completion Dec 4, 2024

Sponsor

Lead sponsor
LB Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Dec 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center inpatient study to evaluate the efficacy and safety of LB-102 in adult patients diagnosed with acutely exacerbated schizophrenia. To determine whether LB-102 administered to patients with acutely exacerbated schizophrenia demonstrates antipsychotic efficacy, as determined by a change from Baseline on the Positive and Negative Syndrome Scale (PANSS) total score, compared to placebo at 28 days. The secondary objectives of the study are to evaluate improvement in CGI-S, safety and tolerability, and pharmacokinetics.

Conditions

  • Schizophrenia

Interventions

  • LB-102Drug

    LB-102 is a dopamine D2/3 and 5HT7 antagonist.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to Week 4 in the PANSS Total ScoreTime frame: Baseline to Day 28 (4 weeks)

Locations

25 sites in 1 country. Site status is shown where the registry gives one.

  • Pillar Clinical Research

    Bentonville, Arkansas

  • Woodland Internation Research Group

    Little Rock, Arkansas

  • Woodland Research Northwest

    Rogers, Arkansas

  • CelExel Clinical Innovations

    Bellflower, California

  • Synexus

    Cerritos, California

  • ProScience Research Group

    Culver City, California

  • CelExel CNS

    Garden Grove, California

  • Synergy Research

    Lemon Grove, California

  • CenExel CIT Riverside

    Riverside, California

  • NRC Research Institute

    Santa Ana, California

  • Behavioral Clinical Research, Inc.

    Hollywood, Florida

  • CenExel RCA

    Hollywood, Florida

  • Segal Institute for Clinical Research

    Miami Lakes, Florida

  • CenExel ACMR

    Atlanta, Georgia

  • CenExel iResearch

    Decatur, Georgia

  • Uptown Research Institute

    Chicago, Illinois

  • Pillar Clinical Research

    Chicago, Illinois

  • CenExel CBH

    Gaithersburg, Maryland

  • CenExel HRI

    Berlin, New Jersey

  • Richmond Behavioral Associates

    Staten Island, New York

  • Midwest Clinical Research Center

    Dayton, Ohio

  • Neuro-Behavioral Clinical Research

    North Canton, Ohio

  • Community Clinical Research

    Austin, Texas

  • InSite Clinical Research

    DeSoto, Texas

  • Pillar Clinical Research

    Richardson, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.